Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study

Maria Gabriella Ferrandina; Giacomo Corrado; Floriana Mascilini; Paola Malaguti; Riccardo Samaritani; Maria Grazia Distefano; Valeria Masciullo; Alessia Di Legge; Antonella Savarese; Giovanni Scambia

doi:10.1186/1471-2407-14-947

Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study

Maria Gabriella Ferrandina, Giacomo Corrado, Floriana Mascilini, Paola Malaguti, Riccardo Samaritani, Maria Grazia Distefano, Valeria Masciullo, Alessia Di Legge, Antonella Savarese, Giovanni Scambia

Risultato della ricerca: Contributo in rivista › Articolo in rivista

18 Citazioni (Scopus)

Abstract

The aim of this multicenter, retrospective study was to evaluate the efficacy and safety of metronomic oral cyclophosphamide (MOC) in heavily treated, relapsed ovarian cancer (ROC) patients.

Lingua originale	English
pagine (da-a)	947-947
Numero di pagine	1
Rivista	BMC Cancer
Volume	14
DOI	https://doi.org/10.1186/1471-2407-14-947
Stato di pubblicazione	Pubblicato - 2014

Keywords

ovarian cancer

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1186/1471-2407-14-947

Altri file e collegamenti

Open Access link a IRIS PubliCatt

Cita questo

Ferrandina, M. G., Corrado, G., Mascilini, F., Malaguti, P., Samaritani, R., Distefano, M. G., Masciullo, V., Di Legge, A., Savarese, A., & Scambia, G. (2014). Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study. BMC Cancer, 14, 947-947. https://doi.org/10.1186/1471-2407-14-947

@article{e297bf55a1f949b48f0c5388e3c19e19,

title = "Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study",

abstract = "The aim of this multicenter, retrospective study was to evaluate the efficacy and safety of metronomic oral cyclophosphamide (MOC) in heavily treated, relapsed ovarian cancer (ROC) patients.",

keywords = "ovarian cancer, ovarian cancer",

author = "Ferrandina, {Maria Gabriella} and Giacomo Corrado and Floriana Mascilini and Paola Malaguti and Riccardo Samaritani and Distefano, {Maria Grazia} and Valeria Masciullo and {Di Legge}, Alessia and Antonella Savarese and Giovanni Scambia",

year = "2014",

doi = "10.1186/1471-2407-14-947",

language = "English",

volume = "14",

pages = "947--947",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd.",

}

Ferrandina, MG, Corrado, G, Mascilini, F, Malaguti, P, Samaritani, R, Distefano, MG, Masciullo, V, Di Legge, A, Savarese, A & Scambia, G 2014, 'Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study', BMC Cancer, vol. 14, pagg. 947-947. https://doi.org/10.1186/1471-2407-14-947

TY - JOUR

T1 - Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study

AU - Ferrandina, Maria Gabriella

AU - Corrado, Giacomo

AU - Mascilini, Floriana

AU - Malaguti, Paola

AU - Samaritani, Riccardo

AU - Distefano, Maria Grazia

AU - Masciullo, Valeria

AU - Di Legge, Alessia

AU - Savarese, Antonella

AU - Scambia, Giovanni

PY - 2014

Y1 - 2014

N2 - The aim of this multicenter, retrospective study was to evaluate the efficacy and safety of metronomic oral cyclophosphamide (MOC) in heavily treated, relapsed ovarian cancer (ROC) patients.

AB - The aim of this multicenter, retrospective study was to evaluate the efficacy and safety of metronomic oral cyclophosphamide (MOC) in heavily treated, relapsed ovarian cancer (ROC) patients.

KW - ovarian cancer

UR - http://hdl.handle.net/10807/67109

U2 - 10.1186/1471-2407-14-947

DO - 10.1186/1471-2407-14-947

M3 - Article

SN - 1471-2407

VL - 14

SP - 947

EP - 947

JO - BMC Cancer

JF - BMC Cancer

ER -

Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo